Compound 23 exhibited specific degradation of BRD4 exclusively in HER2-positive breast cancer cell lines SK-BR-3 and BT474, while being rarely internalized to HER2-negative normal cell lines MCF-7 and MDA-MB 231. This evidence concerns the gene BRD4 and breast carcinoma.